Prognostic factors in acute myeloid leukaemia

被引：40

作者：

Löwenberg, B

机构：

[1] Erasmus Univ, NL-3000 CA Rotterdam, Netherlands

[2] Univ Rotterdam Hosp, NL-3000 CA Rotterdam, Netherlands

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2001年 / 14卷 / 01期

关键词：

prognosis; prognostic factors; acute myeloid leukaemia; cytogenetics; flt-3; receptor; mutations; molecular genetics;

D O I：

10.1053/beha.2000.0116

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The prognosis between subgroups of patients with acute myeloid leukaemia (AML) may range considerably. Haematological, genetic and clinical analysis has provided possibilities for defining the heterogeneity of prognosis. This furnishes clinically relevant insights into the probability of treatment response and survival in individual cases of AML and it provides a lead in treatment management.

引用

收藏

页码：65 / 75

页数：11

相关论文

共 59 条

[1] PROPOSAL FOR THE RECOGNITION OF MINIMALLY DIFFERENTIATED ACUTE MYELOID-LEUKEMIA (AML-MO) [J].

BENNETT, JM ;

CATOVSKY, D ;

DANIEL, MT ;

FLANDRIN, G ;

GALTON, DAG ;

GRALNICK, HR ;

SULTAN, C .

BRITISH JOURNAL OF HAEMATOLOGY, 1991, 78 (03) :325-329

[2]

BERGHINI A, 2000, BLOOD, V95, P726

[3]

Bloomfield CD, 1998, CANCER RES, V58, P4173

[4] Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival [J].

Borg, AG ;

Burgess, R ;

Green, LM ;

Scheper, RJ ;

Yin, JAL .

BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (04) :1083-1091

[5] Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia [J].

Broxterman, HJ ;

Sonneveld, P ;

Pieters, R ;

Lankelma, J ;

Eekman, CA ;

Loonen, AH ;

Schoester, M ;

Ossenkoppele, GJ ;

Löwenberg, B ;

Pinedo, HM ;

Schuurhuis, GJ .

LEUKEMIA, 1999, 13 (02) :258-265

[6] Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for P-glycoprotein expression and activity [J].

Broxterman, HJ ;

Sonneveld, P ;

Feller, N ;

Ossenkoppele, GJ ;

Wahrer, DCR ;

Eekman, CA ;

Schoester, M ;

Lankelma, J ;

Pinedo, HM ;

Lowenberg, B ;

Schuurhuis, GJ .

BLOOD, 1996, 87 (11) :4809-4816

[7] P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy [J].

Broxterman, HJ ;

Sonneveld, P ;

van Putten, WJL ;

Lankelma, J ;

Eekman, CA ;

Ossenkoppele, GJ ;

Pinedo, HM ;

Löwenberg, B ;

Schuurhuis, GJ .

LEUKEMIA, 2000, 14 (06) :1018-1024

[8] Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial [J].

Burnett, AK ;

Goldstone, AH ;

Stevens, RMF ;

Hann, IM ;

Rees, JKH ;

Gray, RG ;

Wheatley, K .

LANCET, 1998, 351 (9104) :700-708

[9] AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR FIRST REMISSION ACUTE MYELOBLASTIC-LEUKEMIA IN PATIENTS OLDER THAN 50 YEARS - A RETROSPECTIVE ANALYSIS OF THE EUROPEAN-BONE-MARROW-TRANSPLANT-GROUP [J].

CAHN, JY ;

LABOPIN, M ;

MANDELLI, F ;

GOLDSTONE, AH ;

EBERHARDT, K ;

REIFFERS, J ;

FERRANT, A ;

FRANKLIN, I ;

HERVE, P ;

GRATWOHL, A ;

GORIN, NC .

BLOOD, 1995, 85 (02) :575-579

[10]

CAMPOS L, 1992, BLOOD, V79, P473

← 1 2 3 4 5 6 →